NeoX Biotech

NeoX Biotech is a pioneering biotechnology company founded in 2018 that is focused on merging AI with biophysics to enhance drug research and development. The company's slogan, "Pioneering AI-driven advancements in immuno-oncology for groundbreaking macromolecular and multispecific drug development," encapsulates its commitment to leveraging cutting-edge technology in the field of immuno-oncology. NeoX Biotech specializes in the discovery and creation of macromolecular and multispecific drugs, with a particular emphasis on immuno-oncology. It has developed a platform for early therapeutic discovery by characterizing protein-protein interactions. In July 2021, NeoX Biotech secured its Series A investment with notable participation from several prominent venture capital firms, including Sky9 Capital, 5Y Capital, BAI Capital, LYFE Capital, Genesis Capital, and Sequoia Capital China. This investment not only signifies the confidence of these influential investors in the potential of NeoX Biotech but also demonstrates the growing interest and support for innovative AI-driven advancements in the biotechnology and health care industries.